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A B S T R A C T
Photothermal therapy (PTT) has captured the attention of different researchers around the world, since the
application of NIR light responsive-nanomaterials has shown promising results in cancer therapy. Gold-core
mesoporous silica shell (Au-MSS) nanoparticles allow the combination of gold mediated PTT with the drug
delivery in order to improve their therapeutic potential. In this study, two different methodologies, electrostatic
or chemical linkage, were explored to functionalize Au-MSS nanorods with TPGS and PEI. For that purpose, the
TPGS and PEI were chemically coupled to each other or modified with 3-(triethoxysilyl)propyl isocyanate. The
produced Au-MSS nanorods display a uniform morphology and a well-defined gold nucleus and silica shell.
Further, the particles surface charge was dependent on the synthesis methodology. The particles modified by
electrostatic interactions (Au-MSS/TPGS-PEI) were slightly negative (−16.9 and −5.1 mV) whereas the for-
mulations produced by chemical linkage (Au-MSS/TPGS/PEI) resulted in positively charged nanoparticles (30.9
and 6.8 mV). The successful incorporation of the polymers was confirmed by Fourier Transformed Infrared
spectroscopy and thermogravimetric analysis. Moreover, the Au-MSS functionalization did not affect the par-
ticles PTT capacity. However, the Au-MSS/TPGS/PEI nanorods displayed a decreased drug encapsulation effi-
ciency. In vitro assays demonstrated the cytocompatibility of Au-MSS up to concentrations of 200 μg/mL,
however the positively charged formulations only remained biocompatible until 100 and 125 μg/mL. Overall,
the attained data confirm the successful modification of Au-MSS nanorods with TPGS and PEI as well as their
applicability as PTT and drug delivery agents.
1. Introduction
Cancer is a major health issue and is responsible for millions of
deaths worldwide [1]. Chemotherapy, radiotherapy and surgical re-
moval remain as the most commonly used treatments for cancer,
however these therapies lack of selectivity and present diverse side
effects [2,3]. Therefore, novel anticancer therapeutic approaches are
currently under investigation, such as immunotherapy [4] and hy-
perthermia-based treatments [5]. Hyperthermia comprises a tissue
temperature increment, up to 39.5–43 °C, in order to damage or even
kill the cancer cells by promoting denaturation of proteins and the
disruption of the cell membrane [6]. The temperature increase can be
mediated by nanomaterials that are able to accumulate preferentially in
the tumor tissue and produce heat in response to specific stimuli, such
as magnetic field and near-infrared (NIR) radiation (i.e. photothermal
effect) [7,8]. So far, several NIR light-responsive nanomaterials, such as
graphene oxide [9], gold [10], polymers [11] and small molecules (e.g.
IR780) [12], have been developed and applied as photothermal agents.
Gold nanoparticles are especially promising devices for photothermal
therapy (PTT) due to their surface plasmon resonance oscillation which
renders them a strong absorption on the NIR region. Further, gold
material is bioinert and presents a high flexibility in terms of shape,
size, and surface chemistry [13–15]. Moreover, gold nanoparticles can
also act as imaging agents for computed tomography, magnetic re-
sonance and photoacoustic imaging, which allow their use in the real-
time monitoring of the therapeutic response as well as the nanoparticles
traffic in the human body [16–19]. However, when bare gold nano-
particles are in contact with biological fluids they tend to aggregate
since they are prone to interact with proteins [20,21]. In addition, the
irradiation of gold nanoparticles with NIR light can compromise their
https://doi.org/10.1016/j.micromeso.2019.04.064
Received 26 November 2018; Accepted 24 April 2019
∗ Corresponding author.CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Avenida Infante D. Henrique, 6200-506, Covilhã,
Portugal.
E-mail address: icorreia@ubi.pt (I.J. Correia).
Microporous and Mesoporous Materials 285 (2019) 1–12
Available online 28 April 2019
1387-1811/ © 2019 Elsevier Inc. All rights reserved.
T
physical integrity due to the heat-mediated nanoparticle reshaping
[22–24]. Thus, the integrity and biocompatibility of the gold nano-
particles decrease as well as their therapeutic potential [22–24]. To
overcome these drawbacks, the gold nanoparticles post-synthesis
modification with different coating materials, such as dextran, poly
(isobutylene-alt-maleic anhydride)-graft-dodecyl, poly(ethylene glycol)
and mesoporous silica, has been widely explored [25–29]. Among
them, the mesoporous silica coating of gold nanoparticles (Au-MSS)
displays promising properties for cancer therapy and imaging [30,31].
Mesoporous silica presents an improved biocompatibility and a large
surface area that can be easily modified with various groups such as
stealthing agents and targeting moieties [32,33]. Further, silica is op-
tically transparent to NIR light and therefore do not compromise the
PTT capacity of the gold core [34,35]. In fact, the inclusion of the silica
shell avoids the gold core degradation upon irradiation with the NIR
light [36,37]. Moreover, the tubular pores of mesoporous silica allow
the encapsulation of drugs and therefore the combination of PTT with
chemotherapy towards a synergistic therapeutic effect [33,38]. How-
ever, it is necessary to avoid the premature drug leakage from the na-
noparticles and increase their blood circulation time to further enhance
the therapeutic outcome [39,40].
Herein, D-α tocopherol polyethylene glycol 1000 succinate (TPGS)
and branched Polyethylenimine (PEI) were combined for the first time
to functionalize Au-MSS nanorods. For that purpose, two different
synthesis procedures were performed comprising the chemical linkage
of the polymers onto the particles surface or the electrostatic bonding of
the TPGS-PEI co-polymer through a simple vortex method. Au-MSS
nanorods were produced with different polymer ratios and their phy-
sicochemical properties as well as cytocompatibility were characterized
to select the most promising nanoparticle formulations. TPGS, a water-
soluble vitamin E derivative, was selected based on its amphiphilic
nature that can at as solubilizer and consequently increase the colloidal
stability of these nanorods [12,41,42]. In addition, TPGS can also act as
an inhibitor of P-gp, a drug efflux pump overexpressed in cancer cells,
and therefore improve the bioavailability of the chemotherapeutics
[42,43]. On the other side, PEI is a cationic polymer routinely used to
bind negatively charged cargos [44]. In these nanorods, PEI will be
attracted to the negatively charged mesoporous silica surface blocking
the particle pores and consequently the drug release.
2. Materials and methods
2.1. Materials
Hydrogen tetrachloroaurate (III) hydrate (HAuCl4) was purchased
from Alfa Aesar (Karlsruhe, Germany). Tetraethylorthosilicate (TEOS)
and tetrahydrofuran (THF) were obtained from Acros Organics (Geel,
Belgium). Hexadecyltrimethylammonium bromide (CTAB) was ac-
quired from Tokyo Chemical Industry (Tokyo, Japan). Hydrochloric
acid (HCl) was purchased to Panreac (Barcelona, Spain). Methanol was
obtained from VWR International (Carnaxide, Portugal). L-ascorbic acid
(AA), silver nitrate (AgNO3), Dulbecco's Modified Eagle medium-high
glucose (DMEM-HG), ethanol (EtOH), ethylenediamine tetraacetic acid
(EDTA), Fluorescein 5-isothiocyanate (FITC), resazurin, sodium bor-
ohydride (NaBH4), Paraformaldehyde, Phosphate-buffered saline (PBS)
solution, D-α tocopheryl polyethylene glycol 1000 succinate (TPGS)
(Mw∼1513 g/mol), Triton-X, 1,1′-Carbonyldiimidazole (CDI),
Branched Polyethylenimine (PEI) (Mw∼1250 g/mol, ρ=1.08 g/mL),
3-(Triethoxysilyl)propyl isocyanate (TESPIC), Toluene and trypsin were
bought from Sigma-Aldrich (Sintra, Portugal). Human negroid cervix
epithelioid carcinoma (HeLa) cells (ATCCs CCL-2t) were acquired from
ATCC (Middlesex, UK). Fetal bovine serum (FBS) was acquired to
Biochrom AG (Berlin, Germany). Wheat germ agglutinin conjugate
Alexa 594® (WGA-Alexa Fluor 594®) and Hoechst 33342® were pur-
chased from Invitrogen (Carlsbad). Doxorubicin hydrochloride (Dox)
was obtained from Carbosynth (Berkshire, UK). Cell imaging plates
were acquired from Ibidi GmbH (Ibidi, Munich, Germany). Cell culture
t-flasks were supplied by Orange Scientific (Braine-l’Alleud, Belgium).
2.2. Synthesis of Au–MSS rods
The nanorods were synthesized through a method comprised of 3
main steps, as previously described in the literature [45]. In the first
step, a seed solution was prepared through the addition of 0.6mL of
NaBH4 (0.01M) under magnetic stirring, to an aqueous solution with
5mL of CTAB (0.2M) and 5mL of HAuCl4 (0.0005M). After 6 h at
30 °C, the seed solution was added to a growth solution, which was
prepared by adding under magnetic stirring 0.03mL of AgNO3 (0.1M),
0.3 mL of HAuCl4 (0.05M) and 0.21mL of AA (0.08M) to an aqueous
solution containing 20mL of CTAB (0.2 M). The resulting solution was
then left undisturbed for 16 h, at 30 °C, to promote the formation of
gold nanorods.
The synthesis of mesoporous silica shell was carried out by adapting
the method described by Dias and co-workers [10]. Initially, the gold
nanorods were centrifuged (12,000 g, for 20min at 25 °C) in order to
remove the excess of CTAB, and resuspended in 10mL of ultrapure
water. Then 0.7 mL of CTAB (0.01M) was added and left under stirring
overnight at 40 °C. Afterward, 0.07mL of NaOH (0.1M) was added to
the solution and mixed over 30min. Then 0.03mL of a solution of TEOS
(20% V/V) in methanol were added. This step was repeated three times,
with intervals of 30min, and the solution was left under stirring for
24 h at 40 °C. The final solution was centrifuged (12,000 g, for 25min at
25 °C) and washed with ultrapure water in order to recover the Au-MSS
nanorods.
2.3. Removal of the surfactant template
The removal of surfactant (CTAB) from Au-MSS nanorods was
performed through a solvent based approach described in the literature
by Moreira and co-workers [46]. The nanoparticles were resuspended
in an acidic solution (HCl 5% v/v in EtOH), sonicated for 2min, and
centrifuged (18,000 g for 15min at 4 °C). This step was repeated several
times, followed by 2 washes in both EtOH (99.9% v/v) and ultrapure
water. The final product was centrifuged and resuspended in ultrapure
water.
2.4. Synthesis of TPGS-PEI branched co-polymer and TPGS-TESPIC and
PEI Branched-TESPIC derivatives
TPGS-PEI Branched co-polymer was synthesized through a method
previously described elsewhere [47,48]. Briefly, TPGS (100mg) was
dissolved in 20mL of dried toluene, under a nitrogen atmosphere, for
6 h at room temperature. Then TPGS was activated with 1,1′-carbo-
nyldiimidazole (CDI) (24mg) and mixed over 24 h, under nitrogen at-
mosphere. Afterward, branched PEI (0.1 mL) was added to the activated
TPGS and left under stirring for 24 h. After the reaction time, the sol-
vent was evaporated (Rotavap®R-215, Büchi, Switzerland) and the re-
maining film was hydrated with ultrapure water, sonicated, dialyzed
and then recovered by freeze-drying. In order to allow the chemical
linkage of TPGS and PEI to the Au-MSS nanorods, the polymers were
modified with TESPIC by adapting a method previously described in the
literature [49,50]. Briefly, TPGS (500mg) or PEI (0.1 mL) were dis-
solved in 20mL of THF under a nitrogen atmosphere and magnetic
stirring, for 6 h at room temperature. Subsequently, TESPIC was added
to the polymer solution and left to react for 24 h. Thereafter, the solvent
was evaporated (Rotavap®R-215, Büchi, Switzerland) and the re-
maining film was hydrated with ultrapure water, sonicated, dialyzed
and freeze-dried. The successful modification of TPGS and PEI Bran-
ched polymers was assessed by performing the Fourier Transform In-
frared (FTIR) analysis of the samples.
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2.5. Au-MSS functionalization
The polymer functionalization of Au-MSS was performed using two
different methodologies. In the first approach, TPGS-PEI Branched co-
polymer was used to modify the nanorods by promoting electrostatic
interactions between the negatively charged mesoporous silica surface
and the positively charged amine groups on PEI. For that purpose, 5 mg
of nanoparticles were resuspended on TPGS-PEI Branched co-polymer
solution (5mg/mL). Then, this solution was vortexed for 1min or 5min
and the particles (Au-MSS/TPGS-PEI) recovered by centrifugation
(4,000 g for 20min at 25 °C) and washed to remove the polymer excess.
Alternatively, TPGS and PEI polymers were chemically linked to the
Au-MSS surface by using a post-synthesis grafting methodology, as
previously described in Ref. [51]. Briefly, Au-MSS nanorods (20mg)
were resuspended in 40mL of EtOH (33%, pH 4), and sonicated for
5min. Then, TPGS-TESPIC and PEI-TESPIC polymers were added to the
nanoparticles solution (ratio 1:1 or 3:1 w/w). After 24 h, the final so-
lution was centrifuged (8,000 g, for 25min at 25 °C) and washed several
times with ultrapure water to recover the Au-MSS/TPGS/PEI nanorods
and remove the solvent.
2.6. Characterization of nanocarriers’ physicochemical properties
The morphology of both coated and uncoated Au-MSS rods was
characterized by Transmission Electron Microscopy (TEM – Hitachi-
HT7700, Japan). The nanoparticles samples were placed on formvar-
coated copper grids and dried at 25 °C, and then the images were ac-
quired at accelerating voltage of 100Kv. After that, nanoparticles total
size, silica shell thickness, and gold core size were measured by soft-
ware (Image J 2.0.0, NIH Image, USA). The success of the Au-MSS
nanorods purification process as well as their functionalization with the
polymers was accessed by acquiring the FTIR spectra of the nano-
particles on a Nicolet iS10 spectrometer, with a 4 cm−1 spectral re-
solution from 600 to 4,000 nm (Thermo Scientific Inc., Massachusetts,
USA). The polymer content on the Au-MSS formulations was measured
by performing the thermogravimetric analysis (TGA) of the samples.
Briefly, uncoated or coated Au-MSS rods were heated up to 600°C, at a
heating rate of 10°C/min under an inert atmosphere on a SDT Q600
equipment (TA Instruments, USA), and the particles’ weight losses were
recorded along time.
The Au-MSS, Au-MSS/TPGS-PEI and Au-MSS/TPGS/PEI nanorods
NIR absorption capacity was evaluated through the acquisition of the
particles’ UV–vis spectra using an UV–vis spectrophotometer (Thermo
Scientific Evolution™ 201 Bio UV–vis Spectrophotometer, Thermo
Fisher Scientific Inc., USA) at a 300 nmmin−1 scanning rate, with a
wavelength range from 200 to 1,100 nm. The zeta potential of coated
and uncoated nanoparticles was determined by using a Zetasizer Nano
ZS equipment (Malvern Instruments, Worcestershire, UK).
2.7. In vitro photothermal measurements
The evaluation of the in vitro photothermal capacity of coated and
uncoated Au-MSS was performed as described in the literature [10].
Thus, nanoparticles at different concentrations (50, 100 and 200 μg/
mL) and a control group with particles were irradiated with a NIR laser
light (808 nm, 1.7W/cm2). The temperature variation of the solution
was measured at different time points (from 1 up to 10min) by using a
thermocouple sensor with an accuracy of 0.1 °C.
2.8. Drug loading
The Dox loading on coated or uncoated Au-MSS rods was performed
through the impregnation of the particles in a Dox solution, as pre-
viously described by Dias and co-workers [45]. Briefly, the Au-MSS
were resuspended in 5mL of methanol containing Dox (40 μg/mL), and
sonicated for 15min. Then, the solution was mixed under stirring for
48 h at room temperature. After that, the drug-loaded nanoparticles
were recovered by centrifugation (18,000 g for 20min at 4 °C) and
freeze-dried. The supernatant was used to quantify the amount of drug
loaded within nanoparticles. Thus, the Dox content was calculated by
measuring the supernatant absorbance at 485 nm (Thermo Scientific
Evolution 201 Bio UV–vis Spectrophotometer, Thermo Fisher Scientific
Inc., USA), and using a calibration curve (ABS= 16.715C-0.0006;
R2=0.9971). The encapsulation efficiency was calculated through
equation (1):
=
−Initial drug weight Drug weight present in the supernatant
Initial drug weight
Encapsulation efficiency (%)
x100
Eq.(1)
2.9. Cytocompatibility assays
2.9.1. Cell viability
The cytocompatibility of coated and uncoated Au-MSS nanorods
was evaluated through a resazurin-based assay [52]. Briefly, HeLa cells
were seeded into 96-well flat bottom culture plates at a density of
10,000 cells per well with 200 μl of DMEM-HG medium. During ap-
proximately 24 h, cells were cultured at 37 °C in a humid atmosphere
containing 5% CO2. Afterward, cells were cultured with different con-
centrations (25–200 μg/mL) of Au-MSS, Au-MSS/TPGS-PEI or Au-MSS/
TPGS/PEI. After 24 and 48 h of incubation, the medium was replaced
and cells were incubated with 10%(v/v) of resazurin(1 mg/mL), at
37 °C and 5% CO2 during 4 h. The produced resorufin present in the
medium was quantified by using a microwell plate reader (Spectramax
Gemini XS, MolecularDevices LLC, USA) at an excitation/emission
wavelength of λex= 560 nm and λem=590 nm. Cells cultured in the
absence of nanoparticles were used as negative control (K−), whereas
cells incubated with EtOH (99.9%) were used as positive control (K+).
2.9.2. Evaluation of the Au–MSS effects on cells’ migration ability
The wound closure assay was performed to evaluate the nano-
particles influence in the HeLa cells' migration ability [10]. For that
purpose, HeLa cells were seeded on 12-well flat bottom culture plates at
a density of 50,000 cells per well, with 2mL of medium. Cells were
maintained in culture (at 37 °C, in a humid atmosphere with 5% CO2),
until reaching confluence. After this period, the medium was removed
and a gap was made by using a micropipette tip. Then, cells were in-
cubated with 100 μg/mL of the different Au-MSS formulations, during
24 and 48 h. A control group without particles was also monitored.
Images were captured by using an Olympus CX41 inverted optical mi-
croscope equipped with an Olympus SP-500 UZ digital camera, and the
cells’ migration distance was measured using Image J software (Image J
2.0.0, NIH Image, USA).
2.9.3. Hemolysis assay
The hemolysis experiments were also performed to evaluate the Au-
MSS nanoformulations impact on blood hemolysis [53]. Briefly, blood
samples freshly obtained from adult mice, were stabilized with EDTA.
Then, the whole blood samples were centrifuged at 500 g, for 5min, at
4 °C in order to recover the red blood cells (RBCs). After that period, the
RBCs were washed three-times with NaCl solution (150mM), diluted in
PBS, distributed by the test tubes, and centrifuged. Afterward, 1mL of
PBS solution containing coated or uncoated Au-MSS nanorods at dif-
ferent concentrations (100, 150, and 200 μg/mL) were added to the
RBC suspension and were incubated at room temperature for 2 and 4 h.
At the same time, the negative (K−) and positive (K+) control were
prepared by adding 1mL of PBS and Triton-X 100, respectively. All the
samples were slightly shaken once for every 30min to resuspend the
RBCs and particles. After the incubation period, the samples were
centrifuged at 500 g for 5min, at 4 °C and 100 μL of supernatants were
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transferred to a 96-well plate to measure the hemoglobin absorbance at
570 nm. RBCs hemolysis percentage was calculated through equation
(2):
=
−
−
Sample Abs Negative Control Abs
Positive Control Abs Negative Control Abs
Hemolysis (%)
Eq.(2)
2.10. Evaluation of the nanoparticle’ cellular uptake
The Au-MSS formulations uptake by HeLa cells was characterized
through confocal laser scanning microscopy (CLSM) following a pro-
tocol previously described by Gaspar and co-workers [54]. For this
purpose, the different Au-MSS nanorods formulations were labelled
with FITC. For the analysis of the nanoparticles cellular uptake, 15,000
HeLa cells were seeded in μ-Slide 8 well Ibidi imaging plates and in-
cubated for 48 h, at 37 °C and 5% CO2. Afterward, cells were incubated
with 200 μg/mL of Au-MSS formulations for 4 h. Subsequently, the
seeded cells were washed with PBS, fixed with paraformaldehyde (4%
w/v) for 10min and rinsed with PBS. For cell nucleus staining, cells
were treated with Hoechst 33342®, whereas the cytoplasm of the cells
was labelled with WGA-Alexa Flour 594®. The CLSM images were then
acquired with a Zeiss LSM 710 Confocal microscope (Carl Zeiss SMT
Inc., Germany) equipped with a Plan Apochromat 63x/1.4 Oil Differ-
ential Interference Contrast objective.
2.11. Statistical analysis
All data are presented as mean ± standard deviation (s.d.).
Oneway analysis of variance (ANOVA) with the
Student–Newman–Keuls post-test was used for multiple groups com-
parison. A p-value lower than 0.05 (p < 0.05) was considered to be
statistically significant. Statistical analysis was performed using
GraphPad Prism v.6.0 software (Trial version, GraphPadSoftware, CA,
USA).
3. Results and discussion
3.1. Synthesis and characterization of TPGS-PEI, TPGS-TESPIC and PEI-
TESPIC polymers
TPGS and PEI were chemically modified to allow the posterior
functionalization of the Au-MSS nanorods. Two different modifications
were investigated, the TPGS linking to PEI through a CDI-mediated
coupling reaction (TPGS-PEI co-polymer) [47,48] and the individual
modification of TPGS and PEI with TESPIC (TPGS-TESPIC and PEI-
TESPIC silane derivatives) through hydrogen-transfer nucleophilic ad-
dition reaction [49,50] (Fig. 1A). The modification of the TPGS-PEI,
TPGS-TESPIC and PEI-TESPIC was confirmed through FTIR analysis
(Fig. 1B). The FTIR spectra of TPGS and TPGS-PEI co-polymer shows
the TPGS characteristic peaks at 1,740 cm−1 and 1,105 cm−1 corre-
sponding to the vibration peak of C]O bond and CeO stretching vi-
bration, respectively [55]. Further, due to the inclusion of the PEI chain
it is also possible to observe the changes in the ratio between the peaks
at 1,146 cm−1 and 1,052 cm−1, which are attributed to the vibration of
the PEI CeN bonds that also occur in the 1145 cm−1 region. The TPGS-
TESPIC spectrum showed a distinctive absorption peak in the 1,680-
1,640 cm−1 region assigned to the newly formed secondary amides.
Moreover, the introduction of the silane moiety on the TPGS backbone
also changed the spectrum in the 1,110-1,050 cm−1 region due to the
absorption band of the SieOeC bonds. Similar results were obtained for
the PEI-TESPIC derivative, where it is possible to identify an absorption
band on the 1,110-1,050 cm−1 region attributed to the SieOeC bonds,
indicating the successful PEI modification with the TESPIC.
3.2. Synthesis and characterization of Au-MSS nanorods
The Au-MSS rods were synthesized by using a seed-mediated
methodology [10,56,57]. The synthesis method involved three main
steps: production by nucleation of small spherical gold particles, that
are then added to a growing solution to form the gold nanorod, and
finally the production of the mesoporous silica shell coating using CTAB
as a soft template to generate the pores. The successful synthesis of Au-
MSS nanorods, with homogeneous distribution and organized in a
single gold-core with a uniform silica shell, was confirmed via TEM
images (please see figure S1). The TEM images show that the gold-core
present a mean length and width of 43 ± 8 nm and 14 ± 3 nm, re-
spectively, corresponding to an aspect ratio (AR) of 3.1. Moreover, the
Au-MSS nanorods presented a mean mesoporous silica shell thickness of
22 nm resulting in particles with a total length and width of 84 ± 10
and 60 ± 4 nm, respectively (Fig. 2A). The obtained gold-core AR is
compatible with the Au-MSS nanorods application in NIR-mediated PTT
applications [58,59]. In fact, ARs between 3 and 4 have been reported
has optimal to absorb the NIR light [58,60]. On the other side, the Au-
MSS overall size still allows them to exploit the enhanced permeability
and retention effect and therefore to accumulate passively in the tumor
tissue [49]. The successful removal of the cytotoxic CTAB molecules
from the Au-MSS was confirmed through FTIR (Fig. 2C). The Au-MSS
nanorods spectra does not contain the two characteristic bands of
CTAB, between 2,950 cm−1 and 2,850 cm−1, which correspond to the
CeH vibration, and 1,450-1,500 cm−1, that is attributed to CH3eN+
deformation [10]. In addition, it is possible to observe the mesoporous
silica shell characteristic peaks in the 1,100 to 750 cm−1 region, that
correspond to SieOeSi, SieO and SieOH vibrations [52]. Therefore,
this data indicates the successful purification of Au-MSS nanorods.
3.3. Synthesis and characterization of Au-MSS/TPGS-PEI and Au-SS/
TPGS/PEI nanoparticles
The Au-MSS nanorods were functionalized using two different ap-
proaches, through electrostatic interaction or by chemical linkage
through a post-synthesis grafting methodology (figure S2). The first
approach is based on the establishment of the electrostatic interactions
between the negatively charged surface of Au-MSS nanorods and po-
sitively charged amine groups on TPGS-PEI co-polymer. The chemical
linkage was performed by promoting the grafting of the TPGS-TESPIC
and PEI-TESPIC silane derivatives on the surface of the Au-MSS na-
norods (figure S1 B, C, and D).
The Au-MSS nanorods surface functionalization was confirmed by
measuring the zeta potential (Fig. 2B). The Au-MSS nanorods displayed
a negative surface charge, −24.3 ± 3.7mV, attributed to the presence
of negatively charged silanol groups on the mesoporous silica surface.
The Au-MSS/TPGS-PEI nanoparticles surface charge was dependent on
the vortex time, the particles vortexed for 1min presented a zeta po-
tential of −5.1 ± 0.2mV. Further, the increase in the vortex time to
5min resulted in a more negative zeta potential, −16.9 ± 0.6mV,
which indicates a lower efficacy on functionalizing the particle surface.
On the other side, the Au-MSS nanorods functionalized with TPGS/PEI
(ratio 1:1) presented a zeta potential of 30.9 ± 5.7mV, whereas the
increase of the TPGS content (ratio 3:1) provoked a decrease on the
surface charge to 6.8 ± 1.2mV. Therefore, these results confirm the
polymers binding to the Au-MSS surface, since the changes observed on
the surface charge are explained by the positively charged amine
groups present on the PEI. Additionally, in the Au-MSS/TPGS/PEI (3:1),
the reduction on the surface charge may also indicate a reduction of the
amount of PEI chains grafted on the particle surface.
As described in the literature, the nanoparticles pharmacokinetic
profile, blood circulation time and biocompatibility are highly influ-
ence by their surface charge [61,62]. In fact, a neutral surface charge
(± 10mV) is until now considered the ideal for nanoparticles circu-
lation, whereas slightly positive particles often present a higher
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internalization by the cells [63,64]. Taking this into account, only the
Au-MSS/TPGS-PEI 1min, Au-MSS/TPGS/PEI (1:1) and Au-MSS/TPGS/
PEI (3:1) formulations were selected for the subsequent studies. The Au-
MSS nanorods modification with the polymers was further confirmed
by FTIR (Fig. 2C). The Au-MSS/TPGS-PEI 1min spectra showed the
characteristic peaks of the silica shell on the 1,100 to 750 cm−1 region
and additionally, the presence of peaks at 2,900 cm−1 and 1,700 cm−1
regions assigned to the TPGS and PEI, respectively. Similar results were
observed on the Au-MSS/TPGS/PEI (1:1) and Au-MSS/TPGS/PEI (3:1)
formulations. Moreover, the successful grafting of the silane modified
polymers on the surface of nanorods was also confirmed by the increase
of the ratio between the SieOeSi peak at 1,045 cm−1 and SieOH peak
at 950 cm−1. Additionally, the Au-MSS nanorods polymer content was
determined by performing a thermogravimetric analysis (Fig. 2D). The
weight losses observed for Au-MSS nanorods were minimal and can be
attributed to the evaporation of water in the interior of the mesopores
and to the loss of the functional hydroxyl groups on the surface of the
particles [65,66]. On the other side, the recorded weight losses were
superior for the Au-MSS/TPGS-PEI, Au-MSS/TPGS/PEI (1:1) and Au-
MSS/TPGS/PEI (3:1), which is attributed to the polymers pyrolysis and
corroborates the successful functionalization of the nanorods by both
methodologies. The calculated polymer content for Au-MSS/TPGS-PEI,
Au-MSS/TPGS/PEI (1:1) and Au-MSS/TPGS/PEI (3:1) was 12%, 10%
and 25%, respectively. The increase of the polymer content with the
increase of the TPGS/PEI ratio on Au-MSS/TPGS/PEI (1:1) and Au-
MSS/TPGS/PEI (3:1) nanorods may be justified by a reduction of the
electrostatic repulsion between the PEI chains, thus favouring the
polymer grafting on the particles surface.
3.4. Drug loading capacity of Au-MSS derivatives
The Au-MSS capacity to encapsulate chemotherapeutic drugs was
characterized by measuring the encapsulation efficiency of Dox. The
Dox loading was promoted by resuspending Au-MSS nanoparticles (i.e.
Fig. 1. Synthesis of TPGS-PEI, TPGS-TESPIC and PEI-TESPIC polymers. (A) Schematic of the synthesis of polymers. (B) FTIR spectra of TPGS, TPGS-PEI, TPGS-TESPIC
and PEI-TESPIC.
C.F. Rodrigues, et al. Microporous and Mesoporous Materials 285 (2019) 1–12
5
Au-MSS and Au-MSS/TPGS/PEI) in Dox solution for 48 h. For the Au-
MSS/TPGS-PEI nanorods, the loading was performed before the Au-
MSS functionalization with the TPGS-PEI co-polymer (Fig. 3A). The
obtained results showed that all the Au-MSS formulations are able to
encapsulate Dox (Fig. 3B). Both Au-MSS and Au-MSS/TPGS-PEI na-
norods presented an encapsulation efficiency superior to 50% (i.e. 10 μg
of Dox per Au-MSS mg). This data indicates that no significant drug
losses occur during the Au-MSS functionalization with the TPGS-PEI co-
polymer. On the other side, the encapsulation efficiency decreased for
around 20% on Au-MSS/TPGS/PEI (1:1) and 30% for on Au-MSS/
TPGS/PEI (3:1) formulations. This decrease on the encapsulation effi-
ciency can be attributed to blockage of the Au-MSS mesopores by the
TPGS and PEI polymers or even to repulsion phenomena between the
positively charged PEI chains and Dox molecules.
Fig. 2. Physicochemical characterization of Au-MSS derivatives. (A) Au-MSS size distribution (length and width included), n= 300. (B) Surface charge analysis of
Au-MSS, Au-MSS/TPGS-PEI and Au-MSS/TPGS/PEI formulations, n= 3. (C) FTIR spectra of Au-MSS, Au-MSS/TPGS/PEI (3:1), Au-MSS/TPGS/PEI (1:1) and Au-
MSS/TPGS-PEI (1 min). (D) TGA analysis of Au-MSS, Au-MSS/TPGS/PEI (1:1), Au-MSS/TPGS/PEI (3:1) and Au-MSS/TPGS-PEI (1 min).
Fig. 3. Characterization of Dox encapsulation efficiency. (A) Schematics of the two methodologies of drug loading for Au-MSS/TPGS/PEI and Au-MSS/TPGS-PEI
formulations. (B) Dox encapsulation efficiency on Au-MSS, Au-MSS/TPGS-PEI (1 min), Au-MSS/TPGS/PEI (3:1) and (1:1) nanorods. Data are presented as
mean ± s.d., *p < 0.05, n = 3.
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3.5. In vitro evaluation of the photothermal capacity of nanoparticles
The potential application of Au-MSS derivatives on PTT was firstly
assessed by acquiring their UV–Vis–NIR absorption spectrum (Fig. 4B).
The Au-MSS nanorods present two characteristics absorption peaks at
515 nm and 750 nm (i.e. NIR region) that correspond to the transverse
and longitudinal resonances, respectively. Moreover, the functionali-
zation with TPGS-PEI or TPGS-TESPIC and PEI-TESPIC did not induced
any significant changes on the absorption capacity of the nanorods. This
strong absorption in the 700–900 nm range support the AueMSS deri-
vatives application in PTT. Further, reduced off-target interactions are
expected since the biologic constituents present a low absorption to this
radiation [67,68].
After confirming the NIR absorption of Au-MSS derivatives, their
capacity to convert optical energy into heat was investigated by mea-
suring the temperature changes induced by the nanoparticles upon NIR
laser irradiation (Fig. 4A). In Fig. 4C, it is possible to observe that all the
Au-MSS derivatives could induce an increase in the temperature when
irradiated with the NIR laser for up 10min. In addition, the polymers
inclusion did not affect the obtained results, being all the formulations
capable to produce a temperature variation of about 40 °C. This in-
crease in the temperature can provoke the denaturation of proteins,
disruption of cells' membrane, dysfunction of metabolic functions and
consequently lead to the cancer cells’ death. Further, it is worth to
notice that even when this assay was performed in complex media (i.e.
DMEM-HG medium supplemented with 10% FBS), the performance of
the Au-MSS/TPGS-PEI, Au-MSS/TPGS/PEI (1:1) and Au-MSS/TPGS/
PEI (3:1) nanorods was not affected (Fig. 4C and D). Such findings,
indicate a good particle stability since the particles aggregation can
induce changes in the absorption spectra of the nanorods and conse-
quently affect their PTT capacity [69,70].
3.6. Nanoparticles cytocompatibility
3.6.1. Cell viability
The cytocompatibility of non-coated Au-MSS nanorods and its
coated derivatives was evaluated on cervical cancer HeLa cells. The
different nanoparticles formulations were incubated for 24 and 48 h
with HeLa cells, at concentrations ranging from 25 to 200 μg/mL
(Fig. 5). The Au-MSS nanorods did not reveal any toxicity towards Hela
cells, being registered cell viabilities superior to 70%, even at a con-
centration of 200 μg/mL. These results are in agreement with different
reports available in the literature, where Au-MSS with a rod-like,
spherical or other shape were biocompatible with HepG2, HeLa and
human dermal fibroblasts [10,71]. Similar results were observed for
Au-MSS/TPGS-PEI nanorods. The HeLa cells incubated with Au-MSS/
TPGS-PEI (1 min) nanorods at concentrations up to 200 μg/mL pre-
sented cell viabilities superior to 80% (Fig. 5B). On the other side, the
Au-MSS/TPGS/PEI (1:1) nanoparticles induced a dose-dependent var-
iation on the cell viability of the HeLa cells (Fig. 5C). The cells pre-
sented a viability of ∼80% at a concentration of 100 μg/mL and con-
tinued to decrease to almost 20% with the increase of the nanoparticles
concentration up to 200 μg/mL. These results can be explained by the
conjugation of the intrinsic anticancer activity of TPGS with the high
positive charge density within the PEI chains, which can lead to de-
stabilization of the cell membrane and cellular necrosis [72]. Therefore,
Fig. 4. Characterization of the PTT capacity of Au-MSS nanorods and its derivatives. (A) Schematics of the evaluation of Au-MSS formulations in vitro PTT capacity.
(B) UV–vis spectra of Au-MSS and derivatives nanorods. (C) Temperature variation curve of Au-MSS derivatives in complex media (DMEM-HG), NIR laser (808 nm,
1.7W cm−2) irradiation for 10min. (D) Temperature variation curve of Au-MSS and Au-MSS derivatives in ultrapure water, NIR laser (808 nm, 1.7W cm−2)
irradiation for 10 min. Data are presented as mean ± s.d., *p < 0.05, n = 3.
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Fig. 5. Evaluation of Au–MSS derivatives cytocompatibility in HeLa cells at 24 and 48 h. (A) Cytocompatibility analysis for Au-MSS, (B) Au-MSS/TPGS-PEI (1 min),
(C) Au-MSS/TPGS/PEI (1:1) and (D) Au-MSS/TPGS/PEI (3:1) nanorods. Positive control (K+): cells treated with EtOH; negative control (K−): cells without na-
noparticles incubation. Data are presented as mean ± s.d., *p < 0.05, n = 5.
Fig. 6. Analysis of the RBCs lysis upon incubation with 100, 150 and 200 μg/mL of Au-MSS, Au-MSS/TPGS-PEI (1 min), Au-MSS/TPGS/PEI (1:1) and Au-MSS/TPGS/
PEI (3:1) nanorods, during 2 (A) and 4 h (B). K−: RBCs incubated with PBS, K+: RBC incubated with Triton-X 100. Data are presented as mean ± s.d., *p < 0.05,
n = 3.
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the Au-MSS/TPGS/PEI (3:1) nanoparticles, which presented a neutral
surface charge 6.8 mV, displayed a superior cell biocompatibility
(Fig. 5D). The results revealed that the HeLa cells treated with Au-MSS/
TPGS/PEI (3:1) nanorods up to 125 μg/mL presented cell viabilities
superior to 70%.
3.6.2. Evaluation of the Au-MSS effect on cells’ migration ability
To further characterize the cytocompatibility of the Au-MSS for-
mulations, the nanoparticles effect on the HeLa cells’ migration ability
was also evaluated (Figure S3 and S4). The obtained results reveal that
both Au-MSS and Au-MSS/TPGS-PEI nanorods did not induce any ne-
gative effect on HeLa cells motility. In Figure S3 A and B, it is possible
to observe that the Control, Au-MSS, and Au-MSS/TPGS-PEI formula-
tions presented almost 45% decrease on the gap width in only 48 h of
incubation. These data are in accordance with the previous works were
Au-MSS nanorods were reported as being biocompatible even when
high concentrations were used [10]. Further, this result also supports
the good cytocompatibility demonstrated by AueMSS/TPGS-PEI na-
norods in the cell viability studies. In the other side, the cells treated
with Au-MSS/TPGS/PEI nanorods presented a higher gap width (Figure
S4 C and D). The Au-MSS/TPGS/PEI (3:1) did not affect the HeLa cells
motility when the concentration was inferior or equal to 100 μg/mL,
whereas the cells incubated with Au-MSS/TPGS/PEI (1:1) showed an
impaired motility even at the lowest tested concentration, i.e. 50 μg/
mL. These results confirm the data obtained during the cell viability
analysis, where the positive charge of PEI impacts the particles cyto-
compatibility by promoting the destabilization of the cell membrane
and cellular necrosis. Further, similarly to the previously observed, the
decrease of the PEI content on the Au-MSS/TPGS/PEI (3:1) formulation
also led to a better biological performance.
Fig. 7. Representative confocal microscopy images of Au-MSS formulations uptake by HeLa cells. The white arrows are pointing to the internalized nanoparticles.
The scale bar corresponds to 50 μm. Blue channel: Hoechst 33342® stained cell nucleus; red channel: WGA-Alexa Fluor 594® stained cell cytoplasm; green channel:
FITC labelled nanoparticles. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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3.6.3. Hemocompatibility
The TPGS and PEI influence on the Au-MSS cytocompatibility was
also evaluated by studying the nanorods hemocompatibility (Fig. 6). In
this way, the RBCs lysis upon incubation for 2 and 4 h with the different
Au-MSS formulations (100, 150, and 200 μg/mL) was evaluated by
UV–vis spectroscopy. The obtained results show that the Au-MSS na-
norods are hemolytic at a concentration of 200 μg/mL since more than
5% of hemoglobin was released after 2 and 4 h of incubation. On the
other side, all the coated formulations presented a safe hemolytic ratio,
ranging the 2% after the 4 h of incubation. These results can be justified
by the neutral surface charges of Au-MSS/TPGS-PEI and Au-MSS-TPGS-
PEI that decreases its interaction with RBCs, as well as by the increased
resistance of healthy cells to the intrinsic activity of TPGS [9]. In fact,
Neophytou et al. verified that TPGS could induce the cancer cells death
via inhibition of Akt phosphorylation and consequent decrease of BcL-2
and Survivin, whereas normal cells are not affected by this action [72].
3.7. Evaluation of the nanoparticle’ cellular uptake
After assessing the cytocompatibility of Au-MSS formulations, the
nanoparticles cellular uptake was evaluated by using confocal micro-
scopy. The nanoparticles' cellular uptake is one of the most important
barriers that drug delivery systems have to overcome when applied in
cancer therapy. In this study, the nanoparticles tracking was achieved
by labelling Au-MSS nanorods with FTIC. In Fig. 7, it is possible to
observe the internalization of all Au-MSS formulations. These data are
in agreement with previous studies where it was demonstrated the
nanorods capacity to transpose the cell membrane, even with a superior
efficiency than the spherical counterparts [10,73,74]. Additionally, the
CLSM images (Fig. 7) also indicate that the functionalization of Au-MSS
nanorods with TPGS and PEI improves the nanoparticles’ uptake. De-
spite the differences in the synthesis methodology, the cells treated with
Au-MSS/TPGS-PEI and Au-MSS/TPGS/PEI (3:1) present a similar
staining by the nanorods, which may be attributed to their neutral
surface charge (i.e. −5.1 and + 6.8, respectively) Surprisingly, the Au-
MSS/TPGS/PEI (1:1) formulation, which presents a highly positive
surface charge, appear to have a lower internalization on HeLa cells
than the other coated nanorods. Such result may be explained by the
higher PEI content that has been associated with the disruption of the
cell membrane and consequent lower cytocompatibility. Altogether,
this data indicates that the synthesis methodology used for functiona-
lizing the Au-MSS nanorods, electrostatic interaction or chemical
linkage, may not influence the nanoparticles cellular uptake. Further,
the Au-MSS/TPGS-PEI and Au-MSS/TPGS/PEI (3:1) formulations were
successfully internalized by HeLa cells, which will allow the drug re-
lease in cell cytoplasm thus avoiding the premature drug degradation
and increasing the therapeutic potential.
4. Conclusion
The Au-MSS nanorods are multifunctional nanomaterials that can
act simultaneously as drug delivery, photothermal and bioimaging
agents. However, it is essential to improve nanoparticles’ circulation
time and release profile when biological applications are intended. For
that purpose, in this study two different methodologies were explored
and optimized to functionalize Au-MSS nanorods with TPGS and PEI in
order to increase the colloidal stability of these nanorods and avoid the
drug leakage. Polymer coated Au-MSS nanorods were produced by
promoting the electrostatic adsorption of TPGS-PEI co-polymer or the
chemical grafting of each polymer individually on the particle surface.
The obtained results demonstrate that the Au-MSS nanorods functio-
nalization did not impact the nanorods overall size and on their PTT
potential. Further, the synthesis methodology and polymer ratio influ-
enced the nanorods surface charge as well as their capacity to en-
capsulate Dox. The in vitro assays, showed that the Au-MSS and Au-
MSS/TPGS-PEI were biocompatible at concentrations up to 200 μg/mL,
whereas these values were slightly lower for Au-MSS/TPGS/PEI (1:1)
and (3:1), 100 and 125 μg/mL respectively. Moreover, the Au-MSS/
TPGS-PEI and Au-MSS/TPGS/PEI (3:1) formulations were successfully
internalized by HeLa cells. Overall, the attained data confirm the suc-
cessful modification of Au-MSS nanorods with TPGS and PEI polymers.
Additionally, the Au-MSS/TPGS-PEI (1 min) formulation showed the
most promising properties, followed by Au-MSS/TPGS/PEI (3:1) na-
norods, for being applied in cancer chemotherapy, PTT and imaging.
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